Treatment satisfaction after 1 year high-power potassium-titanyl-phosphate photoselective vaporization of the prostate.
To investigate the factors that influence treatment satisfaction after high-power potassium-titanyl-phosphate (KTP) laser vaporization of the prostate, we compared the characteristics between patients who were satisfied and those who were not satisfied. In all, 97 patients aged between 53-82 years (median age 67 years) underwent high-power KTP laser vaporization of the prostate for lower urinary tract symptoms due to benign prostatic hyperplasia. At 12 months postoperatively, 60 patients were satisfied with the treatment, whereas 37 were dissatisfied. Although there were no differences in International Prostate Symptom Score (IPSS) values at baseline, the satisfied group scored better in total IPSS at 1, 3, 6, and 12 months postoperatively (P < 0.05). At baseline, the maximum flow rate (Qmax) was lower in the dissatisfied group and remained low throughout the follow-up period, with the exception of 1 month postoperatively (P < 0.05), compared with the satisfied group. There were no differences in other objective data between the two groups, including post-void residual and the number of voids based on the frequency-volume charts. In a multivariate model, a higher bladder contractility index was associated with a greater likelihood of treatment satisfaction 12 months after high-power KTP laser vaporization (odds ratio 1.024, 95% confidence interval 1.001-1.048, P < 0.05). Patients who were not satisfied following the surgery had a smaller improvement in subjective symptoms and Q(max). In addition, our findings suggest that the relative risk of treatment dissatisfaction following high-power KTP laser vaporization was increased in patients with weak detrusor contractility.
Ku
Ja Hyeon
JH
Department of Urology, Seoul National University Hospital, Seoul 100-744, Korea.
Cho
Min Chul
MC
Kim
Hyeong Seok
HS
Paick
Jae-Seung
JS
Kim
Soo Woong
SW
D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D053685:Laser Therapy / Q000379:methods / Q000523:psychology*; D053844:Lasers, Solid-State / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017060:Patient Satisfaction; D011468:Prostatectomy / Q000523:psychology*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000601:surgery*; D011788:Quality of Life; D014555:Urination Disorders / Q000209:etiology / Q000628:therapy
J Endourol. 2006 Aug;20(8):580-5
16903819
J Urol. 2000 Jun;163(6):1730-3
10799170
Urology. 2007 May;69(5):859-63
17482922
J Endourol. 2003 Mar;17(2):93-6
12689402
Clin Ther. 1997 Mar-Apr;19(2):243-58
9152564
BMJ. 1989 Sep 23;299(6702):762-7
2508914
J Urol. 2005 Jan;173(1):158-60
15592063
J Urol. 1992 Nov;148(5):1549-57; discussion 1564
1279218
Int J Clin Pract. 2005 May;59(5):579-90
15857355
Trans Am Assoc Genitourin Surg. 1976;68:29-32
71777
Health Qual Life Outcomes. 2009 Jun 19;7:55
19545384
Value Health. 2004 Mar-Apr;7(2):204-15
15164810
Urology. 2004 Dec;64(6):1155-9
15596189
Scand J Urol Nephrol Suppl. 2004;(215):101-8
15545204
World J Urol. 1995;13(1):47-58
7773317
Asian J Androl. 2006 May;8(3):367-71
16625289
Urology. 2003 Nov;62(5 Suppl 2):3-10
14662401
Rev Urol. 2005 Winter;7(1):1-10
16985801
Eur Urol. 2008 Oct;54(4):893-901
18486311
Eur Urol. 2008 Oct;54(4):902-7
18502565
J Urol. 2002 Aug;168(2):605-9
12131318
Eur Urol. 2009 Jun;55(6):1345-57
19361906
Med Care. 1995 Apr;33(4 Suppl):AS145-55
7536866
Minim Invasive Ther Allied Technol. 2007;16(1):5-10
17365672
Eur Urol. 2006 Jun;49(6):961-9
16632179
Urology. 2009 Apr;73(4):807-10
19200589